CG Bio recently held a global fracture and trauma treatment seminar, “Meet the Masters,” in Bangkok, Thailand.

According to CG Bio, Meet the Masters is an opportunity for Korean and foreign medical professionals to share academic presentations, live demonstrations, and procedural know-how in various fields, including spine, wound care, and aesthetic surgery.

The seminar showcased the latest techniques and clinical applications in trauma surgery and recovery using CG Bio's bone substitute Novosis. Sixty-five medical professionals from Korea, Thailand, Singapore, Indonesia, Malaysia, and other countries attended.

The seminar consisted of three sessions.

In the first session, speakers, including Professor Rahat Jarayabhand from Thailand, shared their cases of treating patients with delayed union and nonunion. In the second session, Dr. Kamarul Arifin bin Abdul Razak from Malaysia and Dr. Andre Yanuar from Indonesia presented the use of bone morphogenetic protein (rhBMP2) in the treatment of iliac defects and infections, femoral nonunion, and post-traumatic iliac complications, respectively. In the third session, Professor Sagong Seung-yup of Ajou University Hospital in Korea presented an in-depth case study on applying Novosys in treating complex trauma.

“Many patients and doctors are benefiting from products like Novosis,” said Professor Jarayabhand of Bhumibol Adulyadej Hospital, Thailand, who served as vice-chair of the seminar. “We hope to continue to share and exchange such cases and know-how in the future.”

“Novosis is more than just a bone-binding treatment. It is a highly effective alternative in treating delayed osseointegration and nonunion, reducing reoperations, and helping patients return to their daily lives faster,” CG Bio CEO Yu Hyun-seung said. “CG Bio will continue to support the discussion of various clinical cases in more countries, provide evidence-based treatment solutions to medical practitioners, and promote Korean technology in the global medical environment.”

Novosis is the world's second and Korea’s first bone substitute with bone morphogenetic protein (rhBMP-2). Its core technology, porous hydroxyapatite (HAp) ceramic, has a structure like human bone, making it highly biocompatible. According to CG Bio, it also significantly reduces the risk of bone growth in unintended places because the bone-forming proteins it is loaded with are released continuously over several months.